Amrutanjan Health Care Ltd (AMRUTANJAN) — Sustainability Report | 28 August 2026

Amrutanjan Health Care Ltd's BRSR filing highlights robust growth in OTC and women's hygiene segments, with 11% revenue and 25% profit growth (pre-exceptional) in FY26, driven by new product launches like Advanced Ortho Pain Relief Oil and Comfy Slimfit XXL Night Pads. The company expanded distribution to 100K chemist outlets by FY27, invested ₹150 crore in a greenfield sanitary napkin plant (commissioned Q1 FY27), and achieved 70% digital process automation (target 100%). ESG disclosures include zero fatalities, 100% renewable energy use, 28 Indian states and 19 international markets served, and ₹1.29 crore CSR spend exceeding mandatory requirements. Governance features 4 independent directors (including 1 woman), SEBI LODR compliance, and robust risk management frameworks. Shareholder communications emphasize dividend clarity (₹2.90/share final), unclaimed dividend transfers to IEPF, and e-voting procedures for the September 23, 2026 AGM.